Unibest

Pharmaceutical intermediates

Zavegepant Intermediates

7 pharmaceutical intermediates for Zavegepant. Indication: Migraine.

提交项目All intermediates

About Zavegepant

Originator
Pfizer Inc
Indication
Migraine
Approved Date
03/09/2023
NCE Patent
03/09/2028
DS/DP
10/07/2031

Available intermediates

7 intermediates currently listed for Zavegepant. Request specifications, documentation or a quotation for any item below.

Zavegepant intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
(R)-METHYL 2-(((BENZYLOXY)CARBONYL)AMINO)-3-(7-METHYL-1H-INDAZOL-5-YL)PROPANOATE855778-40-4//
3-(piperidin-4-yl)quinolin-2(1h)-one hydrochloride855778-84-6//
3-(piperidin-4-yl)quinolin-2(1h)-one205058-78-2//
1-(1-Methyl-4-piperidinyl)piperazine23995-88-2//
methyl (2R)-2-amino-3-(7-methyl-1H-indazol-5-yl)propanoate dihydrochloride1414976-14-9//
1H-Indazole-5-propanoic acid,α-amino-7-methyl-,methyl ester, (αR)-890044-58-3//
1-(1-METHYLPIPERIDIN-4-YL)PIPERAZINE 3HCL349535-15-5//

Other programs under Z

ZelicapavirZipalertinibZiprasidone HydrochlorideZURANOLONE

Building toward Zavegepant?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →